JP7532672B2 - ＦｉｍＨ変異体、それを含む組成物、及びその使用 - Google Patents

ＦｉｍＨ変異体、それを含む組成物、及びその使用 Download PDF

Info

Publication number
JP7532672B2
JP7532672B2 JP2023541784A JP2023541784A JP7532672B2 JP 7532672 B2 JP7532672 B2 JP 7532672B2 JP 2023541784 A JP2023541784 A JP 2023541784A JP 2023541784 A JP2023541784 A JP 2023541784A JP 7532672 B2 JP7532672 B2 JP 7532672B2
Authority
JP
Japan
Prior art keywords
fimh
polypeptide
seq
amino acid
f71mut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023541784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502854A (ja
Inventor
グリープストラ，ヤン
ウェールデンブルグ，エヴリン，マーリーン
ゲウルトセン，イェルーン
フェイ，ケレン，クリスティーナ
ファイツマ，ロウリス，ヤコブ
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2024502854A publication Critical patent/JP2024502854A/ja
Priority to JP2024068916A priority Critical patent/JP2024109576A/ja
Application granted granted Critical
Publication of JP7532672B2 publication Critical patent/JP7532672B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023541784A 2021-01-12 2022-01-11 ＦｉｍＨ変異体、それを含む組成物、及びその使用 Active JP7532672B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024068916A JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21151126.6 2021-01-12
EP21151126 2021-01-12
PCT/IB2022/050166 WO2022153166A1 (en) 2021-01-12 2022-01-11 Fimh mutants, compositions therewith and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024068916A Division JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Publications (2)

Publication Number Publication Date
JP2024502854A JP2024502854A (ja) 2024-01-23
JP7532672B2 true JP7532672B2 (ja) 2024-08-13

Family

ID=74175646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023541784A Active JP7532672B2 (ja) 2021-01-12 2022-01-11 ＦｉｍＨ変異体、それを含む組成物、及びその使用
JP2024068916A Pending JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024068916A Pending JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Country Status (12)

Country Link
US (3) US11725028B2 (enExample)
EP (1) EP4277921A1 (enExample)
JP (2) JP7532672B2 (enExample)
KR (2) KR20250007029A (enExample)
CN (1) CN116888140A (enExample)
AR (1) AR124604A1 (enExample)
AU (1) AU2022207740B2 (enExample)
CA (1) CA3207841A1 (enExample)
IL (1) IL303954B2 (enExample)
MX (1) MX2023008251A (enExample)
TW (1) TW202241929A (enExample)
WO (1) WO2022153166A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
JP2025503423A (ja) * 2021-12-17 2025-02-04 ファイザー・インク ポリヌクレオチド組成物およびその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102974A2 (en) 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6737063B2 (en) 2000-07-07 2004-05-18 Medimmune, Inc. FimH adhesin proteins and methods of use
WO2016183501A1 (en) 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE278419T1 (de) 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
JP2003505030A (ja) * 1999-07-15 2003-02-12 メディミューン，インコーポレーテッド ＦｉｍＨアドヘジンベイストワクチン
WO2001025254A2 (en) 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
ATE398463T1 (de) 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
CA2420234A1 (en) * 2000-08-18 2002-02-28 Medimmune, Inc. Method of administering fimh protein as a vaccine for urinary tract infections
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
AU2006241206B2 (en) 2005-04-26 2011-06-09 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
WO2006119987A2 (en) 2005-05-11 2006-11-16 ETH Zürich Recombinant n-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2716187C (en) 2008-02-20 2020-01-07 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
DK2811981T3 (da) 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
RS65631B1 (sr) 2014-02-24 2024-07-31 Glaxosmithkline Biologicals Sa Novi polisaharid i njegove upotrebe
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
EP3679055A1 (en) * 2017-09-08 2020-07-15 The University of Bristol Protein delivery to membranes
US20190275135A1 (en) * 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against intra-abdominal infections
EP4077372A1 (en) * 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737063B2 (en) 2000-07-07 2004-05-18 Medimmune, Inc. FimH adhesin proteins and methods of use
WO2002102974A2 (en) 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
WO2016183501A1 (en) 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Folia Microbiologica，2019年，Vol.64, No.4，p.587-600
JOURNAL OF BIOLOGICAL CHEMISTRY，2013年，Vol.288, No.33，p.24128-24139
Proteins，2019年，Vol.88, No.4，p.593-603

Also Published As

Publication number Publication date
AR124604A1 (es) 2023-04-12
IL303954A (en) 2023-08-01
KR20230125842A (ko) 2023-08-29
US20250289854A1 (en) 2025-09-18
JP2024109576A (ja) 2024-08-14
WO2022153166A1 (en) 2022-07-21
KR20250007029A (ko) 2025-01-13
US12297238B2 (en) 2025-05-13
IL303954B2 (en) 2025-04-01
EP4277921A1 (en) 2023-11-22
US20220220159A1 (en) 2022-07-14
AU2022207740B2 (en) 2024-06-06
US11725028B2 (en) 2023-08-15
KR102746713B1 (ko) 2024-12-24
CA3207841A1 (en) 2022-07-21
JP2024502854A (ja) 2024-01-23
MX2023008251A (es) 2023-07-26
US20230406890A1 (en) 2023-12-21
CN116888140A (zh) 2023-10-13
TW202241929A (zh) 2022-11-01
AU2022207740A9 (en) 2024-09-05
IL303954B1 (en) 2024-12-01
AU2022207740A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7485771B2 (ja) ＦｉｍＨ変異体、その組成物、及びその使用
US12297238B2 (en) FimH mutants, compositions therewith and use thereof
EA050404B1 (ru) Мутанты fimh, композиции с ними и их применение
HK40118175A (en) Fimh mutant, compositions therewith and use thereof
EA047213B1 (ru) Мутантная форма fimh, композиции на ее основе и их применение
HK40084704A (en) Fimh mutant, compositions therewith and use thereof
HK40084704B (en) Fimh mutant, compositions therewith and use thereof
TW202537972A (zh) FimH突變體、其組成物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231206

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7532672

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150